系统性硬化症患者的共病负担与死亡率
这项回顾性单中心观察研究纳入400例系统性硬化症(SSc)患者,其中74例死亡,记录14种预设共病及SSc相关器官受累情况,采用Kaplan-Meier法和Cox回归分析。结果显示肿瘤、心血管疾病、多重用药及肺、心脏受累与死亡率显著相关,并构建了SSc共病图谱(comorbidome)。
要点
- 肿瘤、心血管疾病和多重用药三种共病与SSc患者死亡率显著相关。
- 肺和心脏两种SSc特异性器官受累与死亡率显著相关。
- 研究构建了SSc共病图谱(comorbidome),揭示共病间相互关联。
核心结论
- 共病是SSc患者的主要问题,中心血管疾病和肿瘤尤为突出,多重用药的影响亦被强调。
- 构建的共病图谱为这一复杂问题提供了全面和分析性视角,并凸显数据的相互关联性。
- 研究受小样本量限制,需在更大规模上验证以确认结果,并可能有助于未来创建死亡率评分工具。
研究设计与样本
- 回顾性、单中心观察性研究,纳入400例系统性硬化症患者。
- 记录人口学信息、生命体征、SSc相关器官受累及14种预设共病的存在与否,并记录初诊和最近就诊日期。
- 采用Kaplan-Meier法构建生存曲线,Cox回归模型进行多变量分析。
主要发现
- 400例参与者中74例死亡。
- 肿瘤、心血管疾病和多重用药三种共病与死亡率显著相关。
- 肺和心脏两种SSc特异性器官受累与死亡率显著相关。
局限性
- 小样本量。
- 需在更大规模上验证以确认结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Systemic sclerosis (SSc) is a serious life-threatening tissue disease. A significant aspect of its mortality arises from comorbid conditions. Our study aimed at mapping out the prevalence of these comorbidities and their relation to mortality, thus creating a 'comorbidome'. METHODS: In our retrospective, single-centre observational study, we recorded each patient's data, including demographic informations, vital stats and SSc-related organ involvement, along with the presence or absence of 14 predefined comorbidities. We also documented the dates of their initial and most recent visits. To construct survival curves, we used the Kaplan-Meier method, followed by a Cox regression model for multivariate analysis. RESULTS: Our study involved 400 participants, 74 of whom unfortunately passed away. It is important to note that three specific comorbidities showed significant correlation to mortality: neoplasia, cardiovascular diseases and polypharmacy, as well as two SSc-specific organ involvements (lung and cardiac). CONCLUSION: Our research led to the successful creation of the SSc comorbidome. Comorbidities are a major concern for patients suffering from SSc, particularly cardiovascular diseases and neoplasms. Our study highlights the effects of polypharmacy. The resultant comorbidome offers a comprehensive and analytical perspective on this complex issue and underscores the inter-relatedness of the data. Our study, however, was limited by a small sample size. Therefore, to confirm our findings, validation on a larger scale is necessary. This could potentially contribute to the creation of a future mortality scoring tool.
引用
- Fauthoux T, Brisou D, Lazaro E, et al. Comorbidity burden on mortality in patients with systemic sclerosis. RMD Open. 2024. PMID: 39424406. doi:10.1136/rmdopen-2024-004637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。